Von Hippel Lindau (VHL) Rabbit Polyclonal Antibody
CNY 1,999.00
CNY 3,280.00
CNY 3,080.00
CNY 300.00
CNY 1,430.00
CNY 2,900.00
CNY 6,650.00
CNY 9,998.00
Specifications
Product Data | |
Applications | IHC, WB |
Recommend Dilution | WB: 500-2000 WB positive control: Human fetal brain tissue IHC: 25-100 Positive control: Human colon cancer Predicted cell location: Cytoplasm |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Immunogen | Full length fusion protein |
Formulation | PBS pH7.3, 0.05% NaN3, 50% glycerol |
Concentration | lot specific |
Purification | Antigen affinity purification |
Conjugation | Unconjugated |
Storage Condition | Store at -20°C as received. |
Gene Name | von Hippel-Lindau tumor suppressor |
Database Link | |
Background | Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B; elongin C; and cullin-2; and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF); which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. |
Synonyms | HRCA1; pVHL; RCA1; VHL1 |
Reference Data | |
Protein Families | Druggable Genome, Transcription Factors |
Protein Pathways | Pathways in cancer, Renal cell carcinoma, Ubiquitin mediated proteolysis |
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
其它Von Hippel Lindau产品